Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
12.5
6.9
Journals
Pharmaceutics
Special Issues
Recent Advances in Antibody–Drug Conjugates for Cancer Therapy
share announcement

Recent Advances in Antibody–Drug Conjugates for Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: 30 April 2027 | Viewed by 913

Editor

Dr. Claudia Parisi

E-Mail Website
Guest Editor
1. Department of Medical Oncology, Thoracic Oncology Unit, Centre Antoine Lacassagne, 06100 Nice, France
2. Department of Translational Medicine and Oncology, Sapienza University of Rome, 00185 Roma, Italy
Interests: lung cancer; targeted therapeutics; predictive biomarkers; digital health applications to mitigate toxicity outcomes with novel biomarker-driven therapies

Special Issue Information

Dear Colleagues,

I am writing to invite you to contribute to a new Special Issue that I am guest editing for Pharmaceutics, titled “Antibody–Drug Conjugates (ADCs) for cancer treatment: from mechanistic insights to clinical translation”.

Antibody–drug conjugates (ADCs) continue to transform oncology, with rapid advances in linker technologies, site-specific conjugation, payload development and biomarker-guided patient selection. This Special Issue aims to highlight current innovations, mechanistic insights, and translational challenges of ADCs across solid malignancies. 

We are delighted to consider proposals for review papers and original articles on subjects including, but not limited to, the following:

  • Foundations and technological advances in ADCs design, including antibody engineering and target selection; linker chemistry and drug release innovations; conjugation manufacturing; payload discovery and mechanisms. 
  • Biomarkers and precision patient selection.
  • Preclinical and translational development, including in vivo and ex vivo models; toxicity mechanisms and safety mitigation; interaction between ADCs and the immune system.
  • Clinical development and therapeutic applications.
  • Future directions and transformative concepts, including industry and regulatory perspectives.

If you are interested in contributing, I would be pleased to discuss potential topics or provide any additional information.

Thank you very much for considering this invitation. I hope to have the opportunity to include your work in this Special Issue.

Dr. Claudia Parisi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ADC
  • solid tumours
  • target selection
  • payload
  • resistance
  • tumour biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

26 pages, 548 KB  
Review
Toxicities of Antibody–Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management
by Luisana Sisca, Mariam Grazia Polito, Arianna Travisani, Fernando Zannino, Michele Iuliani, Giuseppe Tonini and Francesco Pantano
Pharmaceutics 2026, 18(7), 792; https://doi.org/10.3390/pharmaceutics18070792 - 28 Jun 2026
Viewed by 482
Abstract
Background/Objectives: Antibody–drug conjugates (ADCs) have transformed the therapeutic landscape of breast cancer, expanding treatment opportunities across multiple disease settings. However, their increasing clinical use has revealed a heterogeneous spectrum of toxicities that extends beyond conventional chemotherapy-related adverse events. Emerging evidence suggests that ADC-associated [...] Read more.
Background/Objectives: Antibody–drug conjugates (ADCs) have transformed the therapeutic landscape of breast cancer, expanding treatment opportunities across multiple disease settings. However, their increasing clinical use has revealed a heterogeneous spectrum of toxicities that extends beyond conventional chemotherapy-related adverse events. Emerging evidence suggests that ADC-associated toxicities are driven by a complex interplay between ADC structural characteristics, including target antigen expression, payload properties, linker stability, drug-to-antibody ratio, and patient-related susceptibility factors. This review aims to provide a comprehensive overview of ADC-related toxicities in breast cancer, integrating mechanistic insights with clinical management strategies and risk-adapted approaches. Methods: A narrative review of the literature was conducted focusing on clinical trials, real-world studies, translational investigations, and mechanistic evidence related to ADC-associated toxicities in breast cancer. Particular attention was given to the relationship between ADC design, toxicity mechanisms, patient-specific risk factors, and clinical management. Results: ADC-related toxicities encompass a broad range of adverse events, including hematologic toxicity, interstitial lung disease, gastrointestinal complications, hepatotoxicity, peripheral neuropathy, stomatitis, ocular toxicity, dermatologic adverse events, and cardiovascular manifestations. Current evidence indicates that toxicity profiles differ substantially across ADCs and are influenced by multiple factors, including payload class, linker chemistry, target biology, intracellular trafficking, bystander effects, systemic payload exposure, and host-related characteristics. While several toxicities can be anticipated through careful monitoring and early intervention, clinically significant variability remains, and validated predictive biomarkers are largely lacking. Emerging real-world evidence further highlights the importance of individualized toxicity assessment and multidisciplinary management. Conclusions: ADC-related toxicity should be viewed as a multifactorial biological process resulting from the interaction between ADC design and host susceptibility rather than as a uniform class effect. A mechanistic understanding of toxicity pathways may improve risk stratification, toxicity monitoring, and personalized management strategies. Future research should focus on the development of predictive biomarkers, pharmacologic risk models, and next-generation ADC platforms with improved therapeutic indices. This review proposes an integrated framework linking ADC structural determinants, toxicity mechanisms, and clinical management to support safer and more individualized use of ADCs in breast cancer. Full article
(This article belongs to the Special Issue Recent Advances in Antibody–Drug Conjugates for Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop